These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 5641090)

  • 1. The hallucinogenic drugs--their use and abuse.
    Med J Aust; 1968 Jan; 1(4):146-7. PubMed ID: 5641090
    [No Abstract]   [Full Text] [Related]  

  • 2. The current status of the hallucinogenic drugs.
    Seal RE
    Aust N Z J Psychiatry; 1970 Jun; 4(2):64-7. PubMed ID: 5286790
    [No Abstract]   [Full Text] [Related]  

  • 3. The uses and abuses of L.S.D. and other hallucinogenic drugs.
    Barnes DT
    Aust N Z J Psychiatry; 1970 Dec; 4(4):170-3. PubMed ID: 5286778
    [No Abstract]   [Full Text] [Related]  

  • 4. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential.
    Rucker JJ
    BMJ; 2015 May; 350():h2902. PubMed ID: 26014506
    [No Abstract]   [Full Text] [Related]  

  • 5. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of cluster headache to psilocybin and LSD.
    Sewell RA; Halpern JH; Pope HG
    Neurology; 2006 Jun; 66(12):1920-2. PubMed ID: 16801660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics and Personality.
    Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
    ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Return of a problem child.
    Stix G
    Sci Am; 2009 Oct; 301(4):18, 20. PubMed ID: 19780439
    [No Abstract]   [Full Text] [Related]  

  • 10. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey.
    Schindler EA; Gottschalk CH; Weil MJ; Shapiro RE; Wright DA; Sewell RA
    J Psychoactive Drugs; 2015; 47(5):372-81. PubMed ID: 26595349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelic drugs and mystical experience.
    Pahnke WN
    Int Psychiatry Clin; 1969; 5(4):149-62. PubMed ID: 4892137
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
    Ezeaka UC; Kim HJJ; Laprairie RB
    Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High hopes.
    Kupferschmidt K
    Science; 2014 Jul; 345(6192):18-23. PubMed ID: 24994630
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects.
    Hosanagar A; Cusimano J; Radhakrishnan R
    J Clin Psychiatry; 2021 Feb; 82(2):. PubMed ID: 33988926
    [No Abstract]   [Full Text] [Related]  

  • 17. Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.
    Henningfield JE; Coe MA; Griffiths RR; Belouin SJ; Berger A; Coker AR; Comer SD; Heal DJ; Hendricks PS; Nichols CD; Sapienza F; Vocci FJ; Zia FZ
    Neuropharmacology; 2022 Nov; 218():109220. PubMed ID: 35987353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular insights into psychedelic drug action.
    Slocum ST; DiBerto JF; Roth BL
    J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.